| Predicate |
Object |
| contentType |
Comment|Journal Article |
| endingPage |
222 |
| issn |
1361-2611 |
| issueIdentifier |
3 |
| pageRange |
221-222 |
| publicationName |
Evidence-based Cardiovascular Medicine |
| startingPage |
221 |
| bibliographicCitation |
Latour-Pérez J. Adding clopidogrel to aspirin following non-ST elevation acute coronary syndromes may be cost-effective. Commentary. Evid Based Cardiovasc Med. 2005 Sep;9(3):221–4. doi: 10.1016/j.ebcm.2005.06.017. PMID: 16380037. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5ece5ef17344921292ade2f245cc6355 |
| date |
200509 |
| identifier |
https://pubmed.ncbi.nlm.nih.gov/16380037
https://doi.org/10.1016/j.ebcm.2005.06.017 |
| isPartOf |
https://portal.issn.org/resource/ISSN/1361-2611
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/32681 |
| language |
English |
| source |
https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/ |
| title |
Adding clopidogrel to aspirin following non-ST elevation acute coronary syndromes may be cost-effective. Commentary |
| discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2244
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60606
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11015 |